surgeries in ENT, not prespecified
Conditions
Interventions
Group 1: - Patients = 12 Jahre
- Surgery in ENT setting
- doctor's decision to prescribe bromelain tablets hysan is Independent from decistion to include the Patient into the study
Sponsors
URSAPHARM Arzneimittel GmbH
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients = 12 Jahre - Surgery in ENT setting - doctor's decision to prescribe bromelain tablets hysan is Independent from decistion to include the Patient into the study
Exclusion criteria
Exclusion criteria: Due to the non-interventional character of the study, no exclusion criteria are predefined. Contraindications and interactions as described in SPC must be considered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: - Change in clinical symptoms such as pain, oedema, inflammation during the treatment period. - Global judgement of the doctor on the efficacy of the treatment -Reduction in use of analgetics - Continuation of therapy/ planned reapplication of bromelain tablets hysan® Safety: incidence of adverse reactions under treatment judgement on tolerability of the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| descriptive Analysis of data, therefore there is no separate considering of Primary and secondary outcomes. All outcomes are listed in section Primary Outcome. | — |
Countries
Germany
Contacts
Public ContactPeter Meiser
URSAPHARM Arzneimittel GmbH
Outcome results
None listed